hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06361758 id: B2023-326(2) briefTitle: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2026-05-31 date: 2027-05-31 date: 2024-04-12 date: 2024-04-16 name: Shanghai Zhongshan Hospital class: OTHER name: Sun Yat-sen University name: Eastern Hepatobiliary Surgery Hospital briefSummary: This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of immunotheray and antiangiogenic therapy. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Cadonilimab+Lenvatinib measure: Objective Response Rate (ORR) per RECIST v1.1 measure: Objective Response Rate (ORR) per mRECIST measure: Disease control Rate (DCR) measure: Duration of response (DoR) measure: Progression-Free-Survival (PFS) measure: Overall survival Overall survival (OS) measure: Incidence of Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongshan Hospital, Fudan University city: Shanghai state: Shanghai zip: 200032 country: China lat: 31.22222 lon: 121.45806 facility: Sun Yat-sen University Cancer Center) city: Guangzhou country: China name: Li Xu role: CONTACT name: Li Xu role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 facility: Eastern Hepatobiliary Surgery Hospital city: Shanghai country: China name: Kui Wang role: CONTACT name: Jun Xue role: CONTACT name: Kui Wang role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06361745 id: PG-005-6 briefTitle: Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases overallStatus: RECRUITING date: 2024-04-02 date: 2024-12-01 date: 2025-03-01 date: 2024-04-12 date: 2024-04-15 name: PersonGen BioTherapeutics (Suzhou) Co., Ltd. class: INDUSTRY briefSummary: Main purpose:
To evaluate the immunogenicity of UTAA09 injection in R/R AID subjects. conditions: Systemic Lupus Erythematosus conditions: Idiopathic Inflammatory Myopathies conditions: Systemic Sclerosis conditions: IgG4 Related Disease conditions: Primary Sjögren Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: UTAA09 injection primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: T cell injection targeting CD19 chimeric antigen receptor measure: AE measure: Cmax measure: CD19-positive cells measure: Disease remission/response/improvement rates measure: anti-CAR antibody sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: PersonGen.Anke Cellular Therapeutice Co., Ltd status: RECRUITING city: Hefei country: China name: Huimin Meng, Doctor role: CONTACT phone: +86-18015580390 email: huimin.meng@persongen.com lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06361732 id: ILBS-liver Transplant-03 briefTitle: Prevalence of CYP3A5 Polymorphisms in the Donors and ABCB1 Polymorphisms in the Recipients Undergoing Pediatric Liver Transplant and Their Influence on Tacrolimus Levels and Graft Function. overallStatus: RECRUITING date: 2022-12-17 date: 2024-10-30 date: 2024-10-30 date: 2024-04-12 date: 2024-04-12 name: Institute of Liver and Biliary Sciences, India class: OTHER briefSummary: It is known that Immunosuppression post-Liver transplant is central to achieving optimal outcomes in liver transplant recipients. It is required to maintain an adequate balance between reducing rejection and toxicities. Mainstay drugs for maintenance therapy are Calcinuerin inhibitors - Tacrolimus versus cyclosporine. Tacrolimus is preferred, as it has less rejection and better graft survival. However, there is risk of renal and metabolic toxicities. Tacrolimus is bound mainly to alpha1-acid-glycoprotein (encoded by the ABCB1gene) expressed on various epithelial and endothelial cells and lymphocytes. Elimination occurs by metabolizing enzymes of cytochrome P450 system, with biliary excretion (95%) of metabolites (majority) with minority through urine (2.4%). Demethylation and hydroxylation of tacrolimus occurs by hepatic and intestinal CYP3A isoforms (CYP3A4 and CYP3A5). Among the factors that play an important role in the pharmacokinetics of tacrolimus, thus affecting the tacrolimus trough levels in the body and in turn influencing the dosing of the drug required to maintain an adequate balance between reducing rejection and toxicities, genetics plays an important role. Increased expression of CYP3A5 causes more metabolism of tacrolimus and hence affecting the tacrolimus concentration/weight-adjusted dose (C/W-D) ratio in the body. The wild type (CYP3A5\*3) are slow metabolizers and mutant ones (CYP3A5 \*1/\*1 and CYP3A5 \*1/\*3) are fast metabolizers. Fast
metabolizers have a low C/W-D ratio and require higher Tacrolimus dosing and are thus susceptible to renal and metabolic toxicities, EBV viremia and post transplant lymphoproliferative disorder. Polymorphisms in ABCB1 (c.3435C\>T) are also known to influence tacrolimus dosage in the first week of transplant (C/D ratio was lower in ABCB1 3435CC in comparison to CT and TT). There is no such data in pediatric liver transplant setting from Indian subcontinent. The aim of the study is to study the prevalence of CYP3A5 polymorphisms in the donors and ABCB1 polymorphisms in the recipients undergoing Paediatric liver transplant and their influence on Tacrolimus levels and graft function. conditions: Pediatric Liver Transplant studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 80 type: ESTIMATED name: No intervention measure: Time (in days) to achieve transaminases within 1.5 times ULN (60 IU/L) in the pediatric Liver transplant recipients with grafts from slow metabolizer (CYP3A5*3/3 allele) versus fast metabolizer (CYP3A5*1/3 and 1/1 alleles) donors. measure: Prevalence of CYP3A5 alleles in the donors of pediatric liver transplant recipients. measure: Influence of donor CYP3A5 alleles (slow versus fast metabolizers) on tacrolimus concentration-weight adjusted dose ratio at 1 week, 4 weeks, 3 months & 6 months and 1 year after liver transplantation. measure: Prevalence of ABCB1 3435 C/T alleles in the recipients of pediatric liver transplant. measure: Influence of recipient ABCB1 3435 C/T on tacrolimus concentration-weight adjusted dose ratio at 1 week, 4 weeks, 3 months and 6 months and 1 year after liver transplantation. measure: Comparison of the Number of Rejection episodes 1 year from LT. measure: Comparison of proportion of patients who were withdrawn from Mycophenolate or required addition of Mycophenolate 1 year from LT. measure: Comparison of proportion of patients with renal toxicity 1 year from LT. measure: Comparison of proportion of patients with Neurological toxicity 1 year from LT. measure: Comparison of e-GFRand cystatin-C levels in the two cohorts of pediatric liver transplant recipients with grafts from slow metabolizer (CYP3A5*3/3 allele) versus fast metabolizer (CYP3A5*1/3 and 1/1 alleles) donors. sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Institute of Liver and Biliary Sciences status: RECRUITING city: New Delhi zip: 110070 country: India name: Dr Snigdha Verma, MD role: CONTACT phone: 01146300000 email: dr.snigdha1@gmail.com name: Dr Rajeev Khanna, MD role: CONTACT phone: 01146300000 email: drrajeev_khanna@rediffmail.com lat: 28.63576 lon: 77.22445 hasResults: False
nctId: NCT06361719 id: 2312INF briefTitle: Efficacy of Two HMOs in Chinese Infants overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2026-11 date: 2027-06 date: 2024-04-12 date: 2024-04-12 name: Société des Produits Nestlé (SPN) class: INDUSTRY briefSummary: This is a randomized, controlled, double-blind, intervention trial of healthy male and female term infants to evaluate the efficacy of the 2 HMOs on beneficially modulating the gut microbiota, gut maturation, gut barrier integrity, immune response, and other developmental outcomes in healthy Chinese infants. The trial consists of 2 randomized formula-fed groups, and a non-randomized breastfed reference group. conditions: Healthy Infants studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 262 type: ESTIMATED name: Experimental Group (EG) name: Control Group (CG) measure: Bifidobacteria abundance in fecal samples measure: Gut microbiota composition measure: Fecal metabolism measure: Fecal metabolism measure: Fecal markers of intestinal immune health measure: Fecal markers of gut barrier function measure: Fecal markers of gut barrier function measure: Fecal markers of gut barrier function measure: Fecal markers of inflammation measure: Fecal markers of inflammation measure: Fecal markers of inflammation measure: Stool patterns measure: Stool patterns measure: GI symptoms and behaviors measure: Immune competence measure: Infant sleep duration and night-time wakings per 24 hours measure: Infant Health Related Quality of Life measure: Growth measure: Growth measure: Growth measure: Growth measure: Growth measure: Physical Examination measure: Infant Illness measure: Infant illness, infections and medication usage measure: Medication use (type and duration) measure: Formula feeding measure: Breastfeeding measure: Infant dietary pattern sex: ALL minimumAge: 3 Days maximumAge: 14 Days stdAges: CHILD hasResults: False
nctId: NCT06361706 id: 24/047-P briefTitle: VR-Enhanced Psychoeducation for Chronic Pain: A Primary Care Pilot Study acronym: REDOCVR overallStatus: RECRUITING date: 2023-12-04 date: 2025-12 date: 2025-12 date: 2024-04-12 date: 2024-04-26 name: Badalona Serveis Assistencials class: OTHER name: Department of Health, Generalitat de Catalunya briefSummary: This pilot study aims to evaluate the integration of virtual reality (VR) with a psychoeducational program for individuals experiencing chronic pain and central sensitization. Chronic pain significantly hampers daily life, and the condition of central sensitization intensifies this challenge by making the pain more acute. Our research is grounded in the hypothesis that VR, when used to complement conventional psychoeducational methods, can enhance engagement and understanding of pain management strategies, thus potentially improving patient outcomes.
Impact on Chronic Pain Management and Emotional Well-being: Assessed through changes in the Warwick-Edinburgh Mental Well-being Scale (WEMWBS), and the Hospital Anxiety and Depression Scale (HADS) collected at baseline, post-intervention, and 4-8 weeks follow-up Self-management of Chronic Pain: Monitored through the Central Sensitization Inventory (CSI) and changes in patient functionality and mobility using the EuroQol-5D-5L scale, measured at baseline, post-intervention, and 4-8 weeks follow-up.
nctId: NCT06361693 id: APHP240147 id: 2024-A00143-44 type: OTHER domain: France : Ministry of Health briefTitle: Descriptive Observational Study of Patient-performed Pre-oxygenation acronym: ApréOx overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-11 date: 2024-12 date: 2024-04-12 date: 2024-04-15 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: The aim of this research would be to determine the efficacy and effects of preoxygenation when performed by the patient (mask held by the patient).
This is the concept of "self-preoxygenation". conditions: Anesthesia conditions: Anxiety conditions: ASA Physical Status I conditions: ASA Physical Status II studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 110 type: ESTIMATED name: Auto-preoxygenation name: APAIS scale name: Visual analog anxiety scale (VAS-A) name: Visual analog comfort scale (VAS-C) measure: FeO2>90% measure: APAIS anxiety score measure: Visual analog anxiety scale (VAS-A) score measure: Visual analog anxiety scale (VAS-A) score measure: Visual analog comfort scale (VAS-C) score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anesthesia-intensive care department - Cochin - Port-Royal hospital - APHP city: Paris state: Ile De France zip: 75014 country: France name: Sophie TOUSSAINT, Nurse anesthetist role: CONTACT phone: 00 33 1 58 41 45 17 email: sophie.toussaint@aphp.fr name: Claude LE STANG, Nurse anesthetist role: CONTACT email: cch.grouperecherche@gmail.com name: Christophe BAILLARD, PUPH role: SUB_INVESTIGATOR lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06361680 id: Coenzyme Q10 on diabetic child briefTitle: Effect of Coenzyme Q10 on Diabetic Children overallStatus: NOT_YET_RECRUITING date: 2024-10-30 date: 2025-10-30 date: 2025-11-30 date: 2024-04-12 date: 2024-04-12 name: Assiut University class: OTHER briefSummary: Determine the effect of Coenzyme Q10 on random blood sugar and glycosylated haemoglobin conditions: Type 1 Diabetes Mellitus studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: NONE count: 100 type: ESTIMATED name: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets measure: Assess the effect of Coenzyme Q10 on glycated haemoglobin in type 1 diabetes mellitus measure: Control of random blood sugar and glycated haemoglobin in children with type 1 diabetes mellitus . sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06361667 id: 1/02.02.2024 briefTitle: Culture and Well-being: Art as Prescription Therapy ("Art on Prescription") acronym: AoP overallStatus: RECRUITING date: 2024-03-20 date: 2024-12-15 date: 2025-01-15 date: 2024-04-12 date: 2024-04-12 name: KAVADIA ELENI class: OTHER briefSummary: Cluster randomised controlled trial with two arms: arts intervention (any of the arts interventions, see list), which we call here Active Group (AG) vs waitlist control (WL). conditions: Mental Health Issue conditions: Anxiety Disorders conditions: Depressive Disorder conditions: Emotional Disorder conditions: Schizophrenia conditions: Autism studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: We will follow standard practice for RCTs and apply an ANCOVA model to estimate the effects of treatment. The formalism is:
And 1.96 is the critical value for statistical significance at alpha = 0.05. primaryPurpose: TREATMENT masking: NONE count: 384 type: ESTIMATED name: Arts measure: The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) measure: Generalised Anxiety Disorder Assessment (GAD-7) measure: The Patient Health Questionnaire-9 (PHQ-9) measure: UCLA 3-item Loneliness Scale measure: The Strengths and Difficulties Questionnaire (SDQ) sex: ALL minimumAge: 10 Years maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Eleni Kavadia status: RECRUITING city: Athens country: Greece name: Eleni Kavadia role: CONTACT phone: +30 210 6170804 email: ekavadia@epipsi.gr name: Nikos Stefanis, PhD role: PRINCIPAL_INVESTIGATOR lat: 37.97945 lon: 23.71622 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-03-10 uploadDate: 2024-03-26T12:19 filename: Prot_000.pdf size: 390364 hasResults: False
nctId: NCT06361654 id: 2023/0135/OB briefTitle: Effect of Muscular Imbalance Between Flexors and Extensors of the Fingers and Wrist on Upper Limb Injuries in Climbers acronym: CRIMPER overallStatus: RECRUITING date: 2024-03-25 date: 2025-03-25 date: 2025-09-01 date: 2024-04-12 date: 2024-04-15 name: University Hospital, Rouen class: OTHER briefSummary: Climbing is a booming sport with an increasing number of participants. When practicing this sport, there is a muscular imbalance between the flexor and extensor systems (especially in the fingers), with the flexors of the fingers exerting greater force than the extensors. In addition, upper limb injuries, particularly the fingers, are very common.
The study will include measurements on different climbers. Informed consent and personal data will be collected from the climbers before the measurements are taken. The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer. The climbers will then continue their usual training for 1 year. For 1 year after the measurements, the climbers will be contacted every month by telephone to collect the different injuries they may have suffered in relation to climbing, as well as the number of hours they have spent climbing in the past month. After 1 year, the annual number of hours of climbing and the annual number of injuries can be calculated for each climber. Injury is defined as any medically diagnosed lesion of the musculoskeletal system of the upper limb or pain that prevents the practice of a sport whose aetiology is climbing. These data are used to calculate the "athlete exposure" (A-E), i.e. the incidence of injury per 1000 hours of practice. As the study population is large, this allows for variations in exposure between subjects. conditions: Climber studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 47 type: ESTIMATED name: The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer measure: Athlete exposure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rouen, University Hospital status: RECRUITING city: Rouen state: Normandie zip: 76031 country: France name: timothee gillot, phd role: CONTACT phone: 0232880671 phoneExt: +33 email: timothee.gillot@chu-rouen.fr lat: 49.44313 lon: 1.09932 hasResults: False
nctId: NCT06361641 id: 49RC23_0259 id: AO2721-44 type: OTHER domain: ANSM briefTitle: Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes acronym: PHEMOP overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-10-19 date: 2027-10-19 date: 2024-04-12 date: 2024-04-12 name: University Hospital, Angers class: OTHER_GOV briefSummary: Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms conditions: Myeloproliferative Neoplasm conditions: Polycythemia Vera conditions: Essential Thrombocythemia conditions: Primary Myelofibrosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: Monocytes signatures in myeloproliferative neoplasms at diagnosis measure: WHO 2016 criteria for polycythemia vera, prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis measure: Identify correlation between the monocytic signature and driver mutations (mutation in JAK2, CALR or MPL gene). measure: Identify correlation between the monocytic signature and the grade of fibrosis measure: prognostic value of the monocytic signature using a principal component analysis Response criteria according to Barosi et al., Leukemia, vol. 29,1 (2015): 20-6 measure: Prognostic value of the monocyte signature for disease worsening according to Sureau et al., Blood Cancer Journal, vol. 12,4, 56. 8 Apr. 2022 measure: leukemia-free survival measure: myelofibrosis-free survival measure: Monocytes parameters for hematological progression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: GOUBAND Agathe city: Angers state: Maine Et Loire zip: 49933 country: France name: Agathe GOUBAND, PharmD role: CONTACT phone: 02 41 35 55 96 phoneExt: 33 email: Agathe.Gouband@chu-angers.fr name: Damien LUQUE PAZ, PharmD role: CONTACT phone: 02 41 35 53 53 phoneExt: 33 email: Damien.LuquePaz@chu-angers.fr lat: 47.46667 lon: -0.55 facility: BESCOND Charles city: Cholet state: Maine Et Loire zip: 49325 country: France name: Charles BESCOND, MD role: CONTACT phone: 0241355880 email: charles.bescond@ch-cholet.fr lat: 47.06667 lon: -0.88333 facility: TRUCHAN-GRACZYK Malgorzata city: Saumur state: Maine Et Loire zip: 49400 country: France lat: 47.26667 lon: -0.08333 hasResults: False
nctId: NCT06361628 id: RIVER-EU WP4 briefTitle: Implementation and Evaluation of Tailored Interventions to Increase MMR and/or HPV Vaccine acronym: RIVER-EU overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-01 date: 2025-06-01 date: 2024-04-12 date: 2024-04-17 name: University Medical Center Groningen class: OTHER name: Prolepsis Institute for Preventive, Environmental and Occupational Medicine name: University in Zielona Góra name: Pavol Jozef Safarik University briefSummary: The goal of the study is to monitor and evaluate the implementation of interventions that aim to increase HPV \& MMR vaccines among underserved communities across four European countries: Greece, Netherlands, Poland, and Slovakia. The interventions will target identified health systems barriers in an earlier phase of the project. The interventions that will be implemented employ trusted community members as health promotors whom will provide educational sessions on HPV and MMR vaccination to the target groups. In addition, the cost-effectiveness of vaccine uptake strategies for the target groups is being evaluated.
The main research question is: to what extent is the multicomponent tailored intervention effective to increase MMR/HPV intention and vaccine uptake in the target population in Greece, Netherlands, Poland and Slovakia? conditions: Vaccination conditions: Health Systems conditions: Knowledge, Attitudes, Practice studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 1000 type: ESTIMATED name: multicomponent intervention on vaccination awareness measure: Intention to vaccinate MMR and/or HPV by questionnaire measure: Uptake of MMR and/or HPV vaccinations by questionnaire measure: Knowledge concerning MMR and/or HPV vaccinations in the target group using a questionnaire measure: Communication skills of health care professionals using a questionnaire measure: Satisfaction of the stakeholders as measured by a questionnaire measure: Improved access to vaccinations by addressing identified health system barriers - number of barriers addressed sex: ALL minimumAge: 12 Years maximumAge: 100 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Prolepsis city: Athens state: Athene zip: 151 25 country: Greece name: Pania Karnaki role: CONTACT phone: +30 210 6255700 email: p.karnaki@prolepsis.gr name: Nikole Papaevgeniou, PhD role: CONTACT email: n.papaevgeniou@prolepsis.gr lat: 37.97945 lon: 23.71622 facility: University Medical Center Groningen city: Groningen zip: 9713 GZ country: Netherlands name: Janine de Zeeuw, PhD role: CONTACT phone: +31 6 45552994 email: j.de.zeeuw@umcg.nl lat: 53.21917 lon: 6.56667 facility: University of Zielona Gora city: Zielona Góra state: Lubusz zip: 65 417 country: Poland name: Maria Ganczak, MD PhD role: CONTACT email: m.ganczak@inm.uz.zgora.pl lat: 51.93548 lon: 15.50643 facility: PJ Šafárik University city: Košice state: Košice Region zip: 04180 country: Slovakia name: Daniela Fiľakovská, PhD role: CONTACT phone: +421 55 234 3390 email: daniela.filakovska@upjs.sk lat: 48.71395 lon: 21.25808 hasResults: False
nctId: NCT06361615 id: CEC_FP_2023042 briefTitle: Effect of a Dual-task Intervention Program on Physical and Cognitive Function overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-08 date: 2024-03-05 date: 2024-04-05 date: 2024-04-12 date: 2024-04-12 name: University of Americas class: OTHER briefSummary: Aim: to compare the effects of single-task (ST) and dual-task (DT) training on physical and cognitive function in institutionalized older adults in 1 month.